Home › All Companies › CMPX › Annual Report

Compass Therapeutics, Inc. (CMPX) — Annual Report

AI-Powered SEC Filing Analysis

← All CMPX filings
Latest Annual Report Filed: 2026-03-05

Key Insights

  • Compass Therapeutics, Inc. (CMPX) reported strong financial performance in FY 2025, with increases in both research and development as well as general and administrative expenses compared to the prior year.
  • The company continued to advance its pipeline, including late-stage clinical trials for its lead drug candidates CTX10726, CTX8371, and Tovecimig.
  • Compass Therapeutics raised additional capital through an underwritten public offering in August 2025, which included the issuance of pre-funded warrants, providing the company with additional financial resources to support its operations and pipeline development.
Sentiment: Positive Significance: 7/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-03-05. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Compass Therapeutics, Inc.

Quarterly Report Current Report Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.